AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10965417 — intervention group
Group type: COMPARATOR
Intervention: Placebo identical in colour and taste to the active treatment
Number of subjects: 190
Study 8985617 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-Wise Interview with big dolls
Number of subjects: 44
Study 8985617 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-Wise Interview with small, detailed dolls and props
Number of subjects: 44
Study 8985617 — intervention group
Group type: COMPARATOR
Intervention: Step-Wise Interview (control group)
Number of subjects: 44
Study 8985617 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-Wise Interview with dolls (both types)
Number of subjects: 44
Study 8985617 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-Wise Interview with small detailed toys and props
Number of subjects: 44
Study 1281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 10 mg
Number of subjects: 313
Study 1281728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 6145027 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-38,485 (specific thromboxane synthetase inhibitor)
Number of subjects: 30
Study 6145027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30443999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 10 mg
Number of subjects: 87
Study 30443999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Number of subjects: 87
Study 30443999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 29788511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-frequency current (MF, n=12)
Number of subjects: 33
Study 29788511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed current (PC, n=11)
Number of subjects: 33
Study 29788511 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=10)
Number of subjects: 33
Study 27246305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50mg/m2
Number of subjects: 30
Study 27246305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 60mg/m2
Number of subjects: 30
Study 27246305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 70mg/m2
Number of subjects: 30
Study 27246305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80mg/m2
Number of subjects: 30
Study 27246305 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Bevacizumab
Number of subjects: 30
Study 24529041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist communication (expressed competence, honesty, and caring)
Number of subjects: 345
Study 24529041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist communication of caring
Number of subjects: 345
Study 24529041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist communication of honesty
Number of subjects: 345
Study 24529041 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' own oncologist
Number of subjects: 345
Study 21044248 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral plasma vaporization of the prostate (TUVis)
Number of subjects: 52
Study 20084109 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin (1 mg/kg daily for 12 months)
Number of subjects: 113
Study 20084109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mg/kg daily for 12 months)
Number of subjects: 113
Study 20084109 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin with concomitant thyroxin treatment
Number of subjects: 113
Study 20084109 — intervention group
Group type: COMPARATOR
Intervention: Placebo with concomitant thyroxin treatment
Number of subjects: 113
Study 16497334 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 37
Study 16497334 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 37
Study 16497334 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-remitters)
Number of subjects: 37
Study 16497334 — intervention group
Group type: COMPARATOR
Intervention: Control group (adiponectin)
Number of subjects: 37
Study 14740095 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide administration at 3 T
Number of subjects: 0
Study 14740095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative triple-dose 3 T images
Number of subjects: 0
Study 14740095 — intervention group
Group type: COMPARATOR
Intervention: Cumulative triple-dose 1.5 T images
Number of subjects: 0
Study 14740095 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR venography at 3 T
Number of subjects: 0
Study 14740095 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced MR venography at 1.5 T
Number of subjects: 0
Study 11161231 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan/5-FU/LV
Number of subjects: 0
Study 11161231 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 0
Study 9581302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg per day for 5 days)
Number of subjects: 80
Study 9581302 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (100 mg/kg per day for 5 days)
Number of subjects: 80
Study 7800155 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (up to 300 mg per day)
Number of subjects: 4
Study 7800155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 3050906 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg (single dose)
Number of subjects: 150
Study 3050906 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg (2-dose regimen)
Number of subjects: 150
Study 3050906 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 500 mg (2-dose regimen)
Number of subjects: 150
Study 30607981 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) items analysis using Item Response Theory (IRT)
Number of subjects: 1873
Study 31511920 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlas-axis anteroposterior distance (AAAD)
Number of subjects: 140
Study 31511920 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlas-axis lateral distance (AALD)
Number of subjects: 140
Study 31511920 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlantoaxial lateral bending angle (AALB)
Number of subjects: 140
Study 31511920 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlantoaxial rotation angle (AARA)
Number of subjects: 140
Study 29940247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 120
Study 26514619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) with sodium ferrous citrate (SFC) (100 and 115 mg/day)
Number of subjects: 10
Study 26514619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CNT)
Number of subjects: 10
Study 24450608 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (six booklets every fortnight)
Number of subjects: 0
Study 24450608 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 22160495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (2 g/day for 8 weeks)
Number of subjects: 38
Study 22160495 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 38
Study 21056806 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive lidocaine 4 mL mixed with propofol 20 mL
Number of subjects: 80
Study 21056806 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive lidocaine 4 mL mixed with etomidate 20 mL
Number of subjects: 80
Study 21056806 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous treatment with lidocaine 4 mL mixed with propofol 20 mL
Number of subjects: 80
Study 21056806 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous treatment with lidocaine 4 mL mixed with etomidate 20 mL
Number of subjects: 80
Study 17058270 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 17058270 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical MUNE method
Number of subjects: 0
Study 16297689 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/mL rhBMP-2/ACS
Number of subjects: 48
Study 16297689 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.50 mg/mL rhBMP-2/ACS
Number of subjects: 48
Study 16297689 — intervention group
Group type: COMPARATOR
Intervention: Bone graft
Number of subjects: 48
Study 12185767 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulation mode of Vagus nerve stimulation (VNS)
Number of subjects: 10000
Study 12185767 — intervention group
Group type: COMPARATOR
Intervention: Low stimulation mode of Vagus nerve stimulation (VNS)
Number of subjects: 10000
Study 12185767 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 10000
Study 9951675 — intervention group
Group type: EXPERIMENTAL
Intervention: BioComFold IOL
Number of subjects: 30
Study 9951675 — intervention group
Group type: COMPARATOR
Intervention: Foldable control IOL
Number of subjects: 30
Study 7594348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg q.d. plus ampicillin 500 mg b.i.d.
Number of subjects: 24
Study 7594348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d. plus ampicillin 500 mg b.i.d.
Number of subjects: 24
Study 7594348 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (82%)
Number of subjects: 24
Study 7594348 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (73%)
Number of subjects: 24
Study 2130301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 26
Study 2130301 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 26
Study 471256 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (bicycle training and calisthenics, 40 sessions, 4 per week, starting 7-8 weeks after MI)
Number of subjects: 29
Study 471256 — intervention group
Group type: COMPARATOR
Intervention: Control group (31 patients, uniform intervention on primary risk factors and medical therapy)
Number of subjects: 29
Study 30728002 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored SMS intervention (The Step One Program)
Number of subjects: 0
Study 30728002 — intervention group
Group type: COMPARATOR
Intervention: Generic 'thank you' message (Control)
Number of subjects: 0
Study 29160622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed irrigation evacuation (PIE)
Number of subjects: 391
Study 29160622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Number of subjects: 391
Study 29160622 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 391
Study 25581163 — intervention group
Group type: EXPERIMENTAL
Intervention: inchinkoto group, n = 30
Number of subjects: 61
Study 25581163 — intervention group
Group type: COMPARATOR
Intervention: non-inchinkoto group, n = 31
Number of subjects: 61
Study 24431382 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting (from pooled data of 6 global randomized controlled trials: ENDEAVOR and SIRIUS programs)
Number of subjects: 0
Study 24431382 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected predictors for MACCE
Number of subjects: 0
Study 24431382 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected predictors for VTE
Number of subjects: 0
Study 24431382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction and age
Number of subjects: 0
Study 22522672 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg single dose (group B)
Number of subjects: 205
Study 22522672 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg every other day for 15 days (group C)
Number of subjects: 205
Study 22522672 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 205
Study 19221595 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical paromomycin (PR) with methylbenzethonium chloride (MBCL)
Number of subjects: 1221
Study 19221595 — intervention group
Group type: COMPARATOR
Intervention: Topical paromomycin (PR)
Number of subjects: 1221
Study 19221595 — intervention group
Group type: COMPARATOR
Intervention: Parenteral paromomycin (PR)
Number of subjects: 1221
Study 19221595 — intervention group
Group type: COMPARATOR
Intervention: Topical or parenteral paromomycin (PR)
Number of subjects: 1221
Study 17716994 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal polypectomy
Number of subjects: 1673
Study 14691431 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct PTCA
Number of subjects: 0
Study 14691431 — intervention group
Group type: COMPARATOR
Intervention: t-PA
Number of subjects: 0
Study 12538120 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct aortic cannulation (group B)
Number of subjects: 20
Study 12538120 — intervention group
Group type: COMPARATOR
Intervention: Standard femoral cannulation (group A)
Number of subjects: 20
Study 9823137 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-hydroxide paste
Number of subjects: 48
Study 9823137 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid-antibiotic solution
Number of subjects: 48
Study 7704924 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (TOPV) given at birth, 6 weeks, 10 weeks, and 14 weeks after birth
Number of subjects: 452
Study 7704924 — intervention group
Group type: COMPARATOR
Intervention: Control group omitted the dose at birth
Number of subjects: 452
Study 7704924 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPV immunization schedule starting at birth
Number of subjects: 452
Study 2653972 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (2 mg capsules, two on entry and one after each unformed stool up to a maximum of eight per day)
Number of subjects: 50
Study 2653972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 373661 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate, 5 mg
Number of subjects: 20
Study 373661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine sulfate, 25 mg
Number of subjects: 20
Study 373661 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline, 400 mg
Number of subjects: 20
Study 373661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31875646 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 31875646 — intervention group
Group type: COMPARATOR
Intervention: GFRAL-antagonist antibody
Number of subjects: 0
Study 31194950 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL repositioning by scleral suturing
Number of subjects: 104
Study 31194950 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL exchange by retropupillary fixation of an iris claw IOL
Number of subjects: 104
Study 28118453 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 158
Study 28118453 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 158
Study 26466219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2.0mg/kg, max 70mg) associated with midazolam (0.2mg/kg, max 10mg)
Number of subjects: 25
Study 26466219 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1mg/kg, max 5mg) associated with midazolam (0.2mg/kg, max 10mg)
Number of subjects: 25
Study 24416905 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of Traditional Chinese Medicine (TCM)
Number of subjects: 62
Study 24416905 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopy
Number of subjects: 62
Study 17311247 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in relaxation and guided imagery techniques
Number of subjects: 66
Study 17311247 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard training regarding brachytherapy)
Number of subjects: 66
Study 15240190 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta-1b standard dose (250 microg every other day)
Number of subjects: 27
Study 15240190 — intervention group
Group type: COMPARATOR
Intervention: IFN beta-1a (30 microg once-a-week)
Number of subjects: 27
Study 10813504 — intervention group
Group type: EXPERIMENTAL
Intervention: Schistosoma haematobium infection
Number of subjects: 17822
Study 10813504 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and sex-specific prevalence of S. haematobium
Number of subjects: 17822
Study 10813504 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hematuria
Number of subjects: 17822
Study 10813504 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination for hepatomegaly and splenomegaly
Number of subjects: 17822
Study 10813504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography for hepatomegaly
Number of subjects: 17822
Study 10813504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography for splenomegaly
Number of subjects: 17822
Study 10813504 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade III periportal fibrosis
Number of subjects: 17822
Study 10813504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder wall lesions and obstructive uropathy
Number of subjects: 17822
Study 10813504 — intervention group
Group type: EXPERIMENTAL
Intervention: S. mansoni prevalence
Number of subjects: 17822
Study 8772552 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (100-400 ng/kg-day ethinyl estradiol)
Number of subjects: 31
Study 8772552 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 31
Study 1434629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 0
Study 1434629 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 1434629 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol control beverage
Number of subjects: 0
Study 3901721 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 13
Study 3901721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30530597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 100
Study 30530597 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 100
Study 27324320 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Number of subjects: 0
Study 27324320 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26198675 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for mammography screening
Number of subjects: 7400
Study 26198675 — intervention group
Group type: COMPARATOR
Intervention: Usual care (invitation and standard leaflet of the mammography screening programme)
Number of subjects: 7400
Study 25573347 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder tablet (1200 µg allicin/tab) twice daily for 3 months
Number of subjects: 56
Study 25573347 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 56
Study 21071683 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-person mask ventilation using Laerdal self-inflating bag (SIB)
Number of subjects: 48
Study 21071683 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-person mask ventilation using Laerdal self-inflating bag (SIB)
Number of subjects: 48
Study 21071683 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-person mask ventilation using Neopuff (NP)
Number of subjects: 48
Study 21071683 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-person mask ventilation using Neopuff (NP)
Number of subjects: 48
Study 19274696 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 35
Study 19274696 — intervention group
Group type: COMPARATOR
Intervention: Benzyl benzoate lotion
Number of subjects: 35
Study 16798793 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide (1-ppm change)
Number of subjects: 990
Study 16798793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (20-ppb change)
Number of subjects: 990
Study 16798793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfur dioxide (3-day moving sum)
Number of subjects: 990
Study 16798793 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate matter (PM10)
Number of subjects: 990
Study 16798793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone
Number of subjects: 990
Study 12717356 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy approach (n = 14)
Number of subjects: 26
Study 12717356 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal approach (n = 12)
Number of subjects: 26
Study 11028944 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.2 mg at pH 4.0
Number of subjects: 0
Study 11028944 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.2 mg at pH 7.0
Number of subjects: 0
Study 11028944 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.2 mg at pH 9.0
Number of subjects: 0
Study 11028944 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.4 mg at pH 4.0
Number of subjects: 0
Study 11028944 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.4 mg at pH 7.0
Number of subjects: 0
Study 11028944 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.4 mg at pH 9.0
Number of subjects: 0
Study 9200654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg/day
Number of subjects: 43
Study 9200654 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50-100 mg/day
Number of subjects: 43
Study 8256699 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release isosorbide mononitrate 30, 60, 120 or 240 mg once daily
Number of subjects: 313
Study 8256699 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release isosorbide mononitrate 120 or 240 mg once daily
Number of subjects: 313
Study 8256699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 2863998 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg/kg (group A; n = 11)
Number of subjects: 22
Study 2863998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium 1 mg/kg (group F; n = 11)
Number of subjects: 22
Study 2863998 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-induction values)
Number of subjects: 22
Study 30985571 — intervention group
Group type: EXPERIMENTAL
Intervention: Modic changes (MCs) group
Number of subjects: 204